NSE: GLAXO · 9 November 2026
- Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) advanced by 6.71% today, settling at ₹2710.0 after trading within a range of ₹2547.8 and ₹2755.0.
- GlaxoSmithKline Pharmaceuticals Limited reported financial results for the quarter and half year ended September 30, 2026. Standalone revenue from operations reached ₹1179.91 crore, marking a 21% increase compared to ₹973.63 crore in the corresponding quarter of the previous year. Profit after tax before exceptional items stood at ₹334.62 crore, supported by strong execution and operational efficiencies.
- Trading volume was 13.68 times the 20-day average daily volume.
Why is Glaxosmithkline Pharmaceuticals share price rising on 9 November 2026?
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) advanced by 6.71% today, settling at ₹2710.0 after trading within a range of ₹2547.8 and ₹2755.0.
The broader market showed minimal movement, with the Nifty benchmark inching up by 0.06%. However, sector sentiment was strongly supportive, as the Nifty Pharma index advanced 3.42%. GLAXO outperformed both the broader market and its sector index, building on a positive 5-day return of 7.06% and a 20-day return of 6.68%.
The ongoing price momentum follows the company's robust financial disclosure for the quarter ended September 30, 2026, where standalone revenue from operations grew 21% year-on-year to ₹1179.91 crore and profit after tax rose 33% to ₹335.88 crore on a consolidated basis. While the earnings were reported on November 3, 2026, continued investor focus on its portfolio transformation—led by key brands like Augmentin, Calpol, and new innovative products—coincided with today's strong trading session.
8.00 lakh shares traded by 9 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 58,496 shares (13.68 times). The five-day average daily volume was 1.12 lakh shares. Separately, the NSE report for 9 November 2026 showed 1.84 lakh shares delivered, representing 22.94% of that day’s traded volume. The same report recorded 102,813 trades.
The stock's 6.71% gain reflects robust buying interest that outpaced the broader Nifty Pharma sector advance of 3.42%, supported by above-average cash volume and positive sentiment lingering from its recent Q2 FY27 financial results.
Latest Company Developments
GlaxoSmithKline Pharmaceuticals Limited reported financial results for the quarter and half year ended September 30, 2026. Standalone revenue from operations reached ₹1179.91 crore, marking a 21% increase compared to ₹973.63 crore in the corresponding quarter of the previous year. Profit after tax before exceptional items stood at ₹334.62 crore, supported by strong execution and operational efficiencies.
Quarterly earnings updates directly influence fundamental valuations by reflecting revenue expansion, margin trends, and profit growth.
The Board of Directors approved the appointment of M/s Walker Chandiok & Co LLP as the Statutory Auditors of the company for a first term of five consecutive years, commencing from the financial year 2027-28 until the conclusion of the 107th Annual General Meeting, subject to shareholder approval.
Auditor transitions form a key part of corporate governance and ongoing regulatory compliance.
The company announced the appointment of Mr. Sandeep Seth as Head – Ethics & Compliance effective November 3, 2026. Mr. Seth brings over 20 years of experience in compliance and governance across the pharmaceutical and healthcare sectors.
Senior management additions strengthen internal governance and operational oversight within specialized business functions.
GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Appointment of Saneep Seth as Other of the company effective. November 03, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 6.07% on 30 September 2026. This compares with 4.87% on 30 June 2026, a change of +1.20 percentage points.
The filing reported 36 MF/UTI holders.
Research & Brokerage Views
What to Watch Next
- Execution of growth strategies across key promoted brands such as Augmentin, Calpol, and T-Bact
- Uptake and volume expansion of adult immunization categories, particularly Shingrix
- Sustained delivery-to-volume participation patterns relative to the 20-day average volume of 800,450 shares
- Performance trends within the Nifty Pharma sector benchmark
More Glaxosmithkline Pharmaceuticals news and dated analysis →
Frequently Asked Questions
What is the latest Glaxosmithkline Pharmaceuticals company news?
GlaxoSmithKline Pharmaceuticals Limited reported financial results for the quarter and half year ended September 30, 2026. Standalone revenue from operations reached ₹1179.91 crore, marking a 21% increase compared to ₹973.63 crore in the corresponding quarter of the previous year. Profit after tax before exceptional items stood at ₹334.62 crore, supported by strong execution and operational efficiencies.
How strong was Glaxosmithkline Pharmaceuticals’s trading volume?
8.00 lakh shares traded, 13.68 times the 20-day average daily volume. The price and volume data are dated 9 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.